About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Study Finds Decreased Survival for Puerto Rican Women With Triple-negative Breast Cancer Subtype

by Kathy Jones on October 4, 2010 at 8:50 PM
Font : A-A+

 Study Finds Decreased Survival for Puerto Rican Women With Triple-negative Breast Cancer Subtype

A study presented at the Third AACR Conference on The Science of Cancer Health Disparities found that Puerto Rican women who had breast cancer that lacked estrogen and progesterone receptors and did not overexpress the HER2neu protein (triple-negative) had worse survival than those with other types of invasive breast cancer.

"As the incidence of breast cancer rises in Puerto Rico, following U.S. trends, it is important to understand the association of disease subtypes with survival," said Ana P. Ortiz Martinez, M.P.H., Ph.D., associate professor and researcher at the University of Puerto Rico Cancer Center and the department of biostatistics and epidemiology, Graduate School of Public Health, University of Puerto Rico. "Breast cancer is a complex disease, with distinct subtypes with widely differing therapeutic indications and clinical outcomes."

Advertisement

This is the first published study on the impact of tumor subtypes and other clinical factors on breast cancer survival in Puerto Rico.

Researchers analyzed data for 974 female patients with invasive breast cancer who were diagnosed and treated in two main hospitals in Puerto Rico from 2000 to 2005.
Advertisement

The risk of breast cancer death for Puerto Rican women who had the triple-negative breast cancer subtype was more than twice as high as women with other tumor subtypes, even after accounting for a woman's age and cancer stage at diagnosis.

Women who were 50 years old or younger at the time of diagnosis and had regional/distant disease were also more likely to die as a result of their breast cancer.

Of the women studied, 22.5 percent had breast cancer that was HER2neu-positive (meaning that it overexpressed this protein); 60.9 percent of the breast cancers were positive for estrogen or progesterone receptors, but negative for HER2neu; and 16.6 percent were triple negative, neither overexpressing HER2neu nor receptive to estrogen or progesterone.

Findings, which were consistent with results described in previous studies of U.S. populations, will be useful in the development of cancer control strategies in Puerto Rico and may have an impact on future studies of targeted therapies to improve breast cancer survival in other Hispanic populations, said Ortiz Martinez.



Source: Eurekalert
Advertisement

Advertisement
Advertisement

Recommended Reading

Latest Cancer News

Why Is Time of Day Important in Cancer Diagnosis and Treatment?
Chronotherapy (the sleep-wake cycle) is observed as a valuable alternative treatment in cancer diagnosis and treatment.
How Do Neutrophils Impact Pancreatic Cancer Treatment Resistance?
A nanoengineering platform targets neutrophils, the white blood cells without killing pancreatic cancer cells paving the way for effective treatments.
Lung Cancer: The Survival Advantage of Lobectomy Over Wedge Resection
The survival rates between lobectomy and wedge resection surgical procedures were found to be the same among lung cancer patients.
Could TKI Cancer Drugs Lead to Inflammatory Side Effects?
The mechanism by which the kinases cause inflammation has been discovered by scientists.
Are Biomarkers the Key to Identifying Early Pancreatic Risk?
Pancreatic cancer cases are on the rise. The biomarker approach could reduce the chance of developing pancreatic cancer.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Study Finds Decreased Survival for Puerto Rican Women With Triple-negative Breast Cancer Subtype Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests